紫杉醇脂质体联合奥沙利铂和替吉奥治疗晚期胃癌临床观察

Clinical observation of paclitaxel liposome combined with oxaliplatin or S-1 in the treatment of advanced gastric cancer

目的探讨紫杉醇脂质体联合奥沙利铂和替吉奥治疗晚期胃癌的疗效和安全性。方法选择本院收治的70例晚期胃癌患者作为研究对象,应用紫杉醇脂质体联合奥沙利铂和替吉奥方案进行化疗,完成2个周期后进行疗效和不良反应评价,观察本组患者的近期疗效和不良反应。结果 70例患者均可以评价疗效,CR 10例（14.3%）,PR 21例（30.0%）,SD 29例（41.4%）,PD 6例（8.6%）,ORR 44.3%,DCR 85.7%。骨髓抑制是最常见的毒副反应,Ⅰ-Ⅲ度白细胞减少的总发生率为23%,其次胃肠道反应总发生率为16%,其余不良反应均较轻,全组无病例因不良反应终止治疗,治疗相关性死亡者。结论紫杉醇脂质体联合奥沙利铂和替吉奥治疗晚期胃癌疗效确切,不良反应较轻均可以耐受,值得进一步研究应用。

Objective To study the efficacy and safety of paclitaxel liposome combined with oxaliplatin or S-1 in the treatment of advanced gastric cancer. Methods 70 cases of advanced gastric cancer patients treated in our hospital were selected as the research object.The evaluation of efficacy and toxicity was performed after 2 courses, Paclitaxel liposome combined with oxaliplatin or S-1 were administered.The short-term curative effect and adverse reactions were observed. Results Of the 70 patients,there were 10（14.3%）complete remission（CR）,21（30.0%）partial remission（PR）,29（41.4%）stable disease（SD）,6（8.6%）progression disease（PD）,the overall response rate（ORR） was 44.3% and the disease control rate（DCR） was 85.7%.The common toxic effects were bone marrow suppression and the incidence of grade Ⅰ- Ⅲ leucopenia was 23%.The total incidence rate of gastrointestinal reaction was 16%,and the other adverse reactions were mild,There was no case of adverse reaction termination of treatment.No occurrence of treatment related death. Conclusion Paclitaxel liposome combined with oxaliplatin or S-1 is effective and tolerable in the treatment of patients with advanced gastric cancer.